Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10500437 | 0.90 | MRGPRX4 (0.53) | KMT2AMAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL498193 | 0.85 | KMT2A (0.53) | KMT2AMAPTSMN1; SMN2ALDH1A1SLC6A3 | |
| SCHEMBL11490636 | 0.83 | MAPT (0.64) | KMT2AMAPTSMN1; SMN2ALDH1A1SLC6A3 | |
| SCHEMBL27852004 | 0.82 | ESR1 (0.67) | KMT2AMAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL11194302 | 0.81 | MAPT (0.45) | KMT2AMAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL2060064 | 0.81 | KMT2A (0.55) | KMT2AMAPTSMN1; SMN2ALDH1A1SLC6A3 | |
| SCHEMBL9341345 | 0.81 | KMT2A (0.62) | KMT2AMAPTSLC6A3MEN1TDP1 | |
| SCHEMBL9421256 | 0.80 | KMT2A (0.52) | KMT2AMAPTSMN1; SMN2SLC6A3MRGPRX4 | |
| SCHEMBL5706143 | 0.80 | ESR1 (0.56) | KMT2AMAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL10982700 | 0.79 | MAPT (0.57) | KMT2AMAPTALDH1A1SLC6A3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1446388-B1 | 1,2,4-TRIAZOLE DERIVATIVES CONTAINING A SULPHAMATE GROUP AS AROMATASE INHIBITORS | STERIX LTD (GB) | 2013-01-09 | — | — | EP | disclosed |
| US-8148415-B2 | Sulfamic acid ester compounds useful in the inhibition of steroid sulphatase activity and aromatase activity | STERIX LIMITED (GB) | 2012-04-03 | — | — | US | disclosed |
| US-8148415-B2 | Sulfamic acid ester compounds useful in the inhibition of steroid sulphatase activity and aromatase activity | STERIX LIMITED (GB) | 2012-04-03 | — | — | US | disclosed |
| US-8148415-B2 | Sulfamic acid ester compounds useful in the inhibition of steroid sulphatase activity and aromatase activity | STERIX LIMITED (GB) | 2012-04-03 | — | — | US | disclosed |
| US-7745472-B2 | Compound | STERIX LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-7745472-B2 | Compound | STERIX LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-20090111862-A1 | Compound | RICHTER GEDEON NYRT. (HU) | 2009-04-30 | — | — | US | disclosed |
| US-20090111862-A1 | Compound | RICHTER GEDEON NYRT. (HU) | 2009-04-30 | — | — | US | disclosed |
| US-7361677-B2 | Polycyclic sulphamate compounds suitable for use as inhibitors of aromatase and/or sulphatase | STERIX, LTD. (GB) | 2008-04-22 | — | — | US | disclosed |
| US-7361677-B2 | Polycyclic sulphamate compounds suitable for use as inhibitors of aromatase and/or sulphatase | STERIX, LTD. (GB) | 2008-04-22 | — | — | US | disclosed |
| US-20070213383-A1 | Sulfamic acid ester compounds useful in the inhibition of steroid sulphatase activity and aromatase activity | STERIX LIMITED (GB) | 2007-09-13 | — | — | US | disclosed |
| US-20070213383-A1 | Sulfamic acid ester compounds useful in the inhibition of steroid sulphatase activity and aromatase activity | STERIX LIMITED (GB) | 2007-09-13 | — | — | US | disclosed |
| US-20070213383-A1 | Sulfamic acid ester compounds useful in the inhibition of steroid sulphatase activity and aromatase activity | STERIX LIMITED (GB) | 2007-09-13 | — | — | US | disclosed |
| EP-1765792-A1 | SULFAMIC ACID ESTER COMPOUNDS USEFUL IN THE INHIBITION OF STEROID SULPHATASE ACTIVITY AND AROMATASE ACTIVITY | Sterix Limited (GB) | 2007-03-28 | — | — | EP | disclosed |
| US-20060241173-A1 | A sulfamate compound, especially a sulfamylated flavone, isoflavone or flavanone, that is an inhibitor of both estrone sulfatase activity and aromatase activity for treating breast and endometrial cancers | STERIX LTD. | 2006-10-26 | — | — | US | disclosed |
| WO-2005115996-A1 | SULFAMIC ACID ESTER COMPOUNDS USEFUL IN THE INHIBITION OF SEROID SULPHATASE ACTIVITY AND AROMATASE ACTIVITY | STERIX LIMITED (GB) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111862-A1 | Compound | QPCT, SQOR, SDHA | KMT2A 880/4885MAPT 3143/4885SMN1; SMN2 4170/4885 |
| US-20060241173-A1 | A sulfamate compound, especially a sulfamylated flavone, isoflavone or flavanone, that is an inhibitor of both estrone sulfatase activity and aromatase activity for treating breast and endometrial cancers | STS, SULT1E1, CYP19A1 | KMT2A 1225/4885MAPT 3852/4885SMN1; SMN2 4304/4885 |
| US-20070213383-A1 | Sulfamic acid ester compounds useful in the inhibition of steroid sulphatase activity and aromatase activity | STS, SULT1E1, CYP19A1 | KMT2A 1340/4885MAPT 4825/4885SMN1; SMN2 4413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.